Atrial Fibrillation: Abelacimab Treatment Study

We are studying whether abelacimab can help high-risk patients with atrial fibrillation who cannot take oral blood thinners. The goal is to see if it reduces the risk of strokes and other serious complications compared to a placebo.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Abelacimab

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Mnogoprofilna Bolnitsa Za Aktivno Lechenie Puls AD
Cardiology department
Blagoevgrad, Bulgaria
Universitetska Mnogoprofilna bolnica za aktivno lechenie Deva Maria EOOD
Clinic of Сardiology
Dulovo, Bulgaria
Multiprofile Hospital For Active Treatment-Uni Hospital Ltd.
Clinic of cardiology
Elin Pelin, Bulgaria

Sponsor: Anthos Therapeutics Inc.
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.